DNMT inhibitors and particularly hypomethylating agents, such as azacytidine and decitabine, have a biological impact (viability, proliferation) on K562 and KCL22 myelogenous cells and primary CD34+ BC-CML cells [34,44,112], unpublished personal data]. This evidence concerns the gene CD34 and chronic myelogenous leukemia, BCR-ABL1 positive.